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ABSTRACT
Introduction: Immune-mediated inflammatory
diseases (IMIDs) are chronic autoimmune con-
ditions that share common pathophysiologic
mechanisms. The optimal management of
patients with IMIDs remains challenging
because the coexistence of different conditions
requires the intervention of several specialists.
The aim of this study was to develop a series of
statements defining overarching principles that
guide the implementation of a multidisci-
plinary approach for the management of
spondyloarthritis (SpA)-related IMIDs including
SpA, psoriasis, psoriatic arthritis, Crohn’s dis-
ease, ulcerative colitis and uveitis.
Methods: A Delphi consensus-based approach
was used to identify a core set of statements.
The process included development of initial
questions by a steering committee, an exhaus-
tive search of the literature using complemen-
tary approaches to identify potential statements
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and two Delphi voting rounds for finalization of
the statements.
Results: Consensus was achieved on the related
nature of IMIDs, the existence of a high preva-
lence of multiple IMIDs in a single patient and
the fact that a multidisciplinary approach can
result in a more extensive evaluation and com-
prehensive approach to treatment. The goals of
a multidisciplinary team should be to increase
diagnosis of concomitant IMIDs, improve the
decision-making process, and increase patient
satisfaction and adherence. Early referral and
diagnosis, early recognition of concomitant
IMIDs and optimizing treatment to improve
patient quality of life are some of the advan-
tages of using multidisciplinary teams. To be
effective, a multidisciplinary team should be
equipped with the appropriate tools for diag-
nosis and follow-up, and at a minimum the
multidisciplinary team should include a der-
matologist, gastroenterologist and rheumatolo-
gist; providing psychologic support via a
psychologist and involving an ophthalmologist,
general practitioners and nurses in multidisci-
plinary care is also important.
Conclusion: The present Delphi consensus
identified a set of overarching principles that
may be useful for implementation of a
multidisciplinary approach for the manage-
ment of SpA-related IMIDs.
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INTRODUCTION
The term ‘‘immune-mediated inflammatory
diseases’’ (IMIDs) defines a group of chronic
autoimmune conditions that share common
pathophysiologic mechanisms [1, 2]. A large
body of evidence shows that multiple IMIDs can
coexist within the same patient and within
families, as a consequence of shared genetic
predisposing factors [1, 3]. The fact that distinct
IMIDs, including psoriasis (Pso), psoriatic
arthritis (PsA), spondyloarthritis (SpA) and
inflammatory bowel disease (IBD), may be
effectively treated by targeting the same
inflammatory mediator [e.g., tumor necrosis
factor-a (TNF-a)] further demonstrates a com-
mon underlying pathophysiology [2, 4].
With the introduction of biologic therapies
over the past 2 decades, remarkable progress has
L. Bianchi
U.O.C. Dermatologia, Fondazione Policlinico Tor
Vergata, Tor Vergata University of Rome, Rome,
Italy
L. Cimino
SSD di Immunologia Oculare, AUSL-IRCCS Reggio
Emilia, Reggio Emilia, Italy
A. Costanzo
Unita` Dermatologia Dipartimento di Scienze
Biomediche Humanitas University, Rozzano, Milan,
Italy
A. Costanzo
UOC Dermatologia IRCCS Istituto Clinico
Humanitas, Rozzano, Milan, Italy
A. Cristaudo
UO Dermatologia, MST, Ambientale e Tropicale San
Gallicano Dermatological Institute-IRCCS, Rome,
Italy
M. Daperno
Gastroenterology Unit, Mauriziano Hospital, Turin,
Italy
A. C. Fostini  P. Gisondi  G. Girolomoni
Section of Dermatology and Venereology,
Department of Medicine, University of Verona,
Verona, Italy
M. Galeazzi
Dipartimento di Scienze Mediche, Chirurgiche e
Neuroscienze, Universita` degli Studi di Siena, Siena,
Italy
M. Gilio
Department of Health Science, University ‘‘Magna
Grecia’’, Catanzaro, Italy
P. Gionchetti
IBD Unit, Department of Medical and Surgical
Sciences, S. Orsola-Malpighi Hospital, University of
Bologna, Bologna, Italy
E. Lubrano
Dipartimento di Medicina e Scienze della Salute
‘‘Vincenzo Tiberio’’, Universita` degli Studi del
Molise, Campobasso, Italy
546 Adv Ther (2018) 35:545–562
been achieved in the treatment of individual
IMIDs. However, optimal management of
patients with IMIDs remains challenging
because the coexistence of different conditions
requires the intervention of several specialists,
typically a rheumatologist, dermatologist and
gastroenterologist. Validated strategies for an
integrated and comprehensive assessment and
treatment of IMIDs that consider all disease
manifestations, instead of considering each
IMID individually, are lacking or are just begin-
ning to emerge in various settings, including
SpA, IBD and psoriatic disease [5–8]. The design
of such strategies is complex and requires a close
collaboration between specialists.
As far as the management of IMID patients is
concerned, multidisciplinary care provided by a
team composed of several healthcare profes-
sionals is considered a valuable approach and is
widely recommended. For example, the guide-
lines for the management and treatment of
rheumatoid arthritis (RA) patients issued in
2009 by the UK National Institute for Health
and Clinical Excellence (NICE) emphasize the
importance of comprehensive management of
patients with RA [9]. Recommendations from
many scientific societies for the main SpA-re-
lated IMIDs, including PsA and axial SpA, stress
the importance of the multidisciplinary
approach in the management of these diseases.
Overarching principle 2 from the 2015 GRAPPA
treatment recommendations for patients with
PsA states that ‘‘Multidisciplinary and multi-
specialty assessment and management will be
most beneficial for individual patients’’ [10], the
2015 update of the EULAR recommendations
for the management of PsA overarching princi-
ple C states that ‘‘Rheumatologists are the spe-
cialists who should care for the musculoskeletal
manifestations of patients with PsA; in the
presence of clinically significant skin involve-
ment a rheumatologist and a dermatologist
should collaborate in diagnosis and manage-
ment’’ [6], and the 2016 update of the ASAS-
EULAR management recommendations for
axial SpA overarching principle 1 states that
‘‘Axial SpA is a potentially severe disease with
different manifestations, usually requiring
multidisciplinary management coordinated by
the rheumatologist’’ [11].
However, the evidence supporting the effec-
tiveness of this strategy is very limited. Most
clinical studies comparing management by a
multidisciplinary team with conventional
management are from the rheumatology field
and their results are controversial [12, 13].
Moreover, establishing a multidisciplinary team
is a demanding process that may not be feasible
[14–16]. The composition of the multidisci-
plinary team and other characteristics may vary
according to different settings. However,
regardless of the setting, formal coordination of
the team and common definition of the goals
are crucial for the successful implementation of
this approach [14].
To encourage the adoption of a multidisci-
plinary approach for the management of SpA-
related IMIDs including SpA, Pso, PsA, IBD
[Crohn’s disease (CD) and ulcerative colitis
(UC)] and uveitis, a panel of experts in
rheumatology, dermatology, gastroenterology
and ophthalmology set out to define overarch-
ing principles that guide the implementation of
such an approach. Toward this aim, questions
addressing the relevant issues regarding multi-
disciplinary care for SpA-related IMIDs were
drafted by a steering committee, and a system-
atic review of the literature was performed to
answer these questions, producing preliminary
statements. Two rounds of Delphi were then
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conducted among the panel of experts to iden-
tify the final 13 consensus statements presented
in this article, each referring to one of the dis-
cussed questions. The main objective of these
statements is to inform dermatologists, gas-
troenterologists and rheumatologists about the
rationale and value of an integrated approach to
SpA-related IMIDs and to promote and guide
towards the institution of multidisciplinary
teams for the management of patients affected
by these conditions.
METHODS
The consensus statements presented in this
article were produced within the BRIDGE (Be
Refocused on Immunology, Dermatology, Gas-
troenterology and Rheumatology) project,
aimed at promoting collaboration among IMID
specialists. The main objective of the process
was to produce a series of statements defining
overarching principles of the multidisciplinary
management of SpA-related IMIDs including
SpA, Pso, PsA, CD, UC and uveitis, supported by
published evidence or based on expert consen-
sus. Consensus was generated by means of a
modified Delphi method, an interactive tech-
nique that develops consensus in two or more
rounds of questions submitted to a panel of
experts [17–19]. The consensus-finding process
(Fig. 1) consisted of three phases (phases 1, 2
and 3) and took from April 2016 to March 2017
to complete. This article does not contain any
novel studies with human or animal subjects
performed by any of the authors.
Phase 1
In April 2016, a steering committee composed
of a dermatologist (GG), gastroenterologist (FR)
and rheumatologist (IO) met to identify IMID
experts who could be part of the scientific board
to define the objectives and topics covered by
the statements and to plan the entire consen-
sus-finding process. The IMID experts, seven
rheumatologists, seven dermatologists, six gas-
troenterologists and one ophthalmologist, were
selected based on their publication record in the
IMID field and previous contributions to similar
activities; most of these experts had direct
experience (i.e., clinical practice) in the multi-
disciplinary management of SpA-related IMIDs.
The steering committee drafted nine questions
addressing relevant issues associated with the
multidisciplinary approach to SpA-related
IMIDs and proposed answers based on pub-
lished evidence and expert opinion. The ques-
tions addressed the following issues: (1) the
context and rationale for adopting a multidis-
ciplinary approach; (2) the value of the multi-
disciplinary approach throughout all stages of
patient management; (3) goals of the multidis-
ciplinary team; (4) composition of the multi-
disciplinary team. To provide further evidence-
based support to the answers, a systematic
review of the literature was planned. In a second
meeting held in July 2016 and attended by the
entire scientific board (steering committee and
experts), the nine questions and their answers
were finalized and the details of the systematic
search of the literature were established.
Phase 2
A systematic PubMed search was performed using
pre-defined key words and inclusion criteria.
Based on the evidence extracted from the selected
articles, the answers to the nine questions were
definedand produceda totalof52statements.Ata
third meeting held in October 2016, the prelimi-
nary version of the statements was presented to
the scientific board; the statements were then
reviewed and finalized to produce the first version
of the statements to be submitted to the first
round of the Delphi process. Great care was taken
to reduce redundancy and to improve the clarity
and readability of the statements. The questions
were reduced from 9 to 7 and the number of
related statements was reduced from 52 to 13 by
removing repetitions and, when possible, by col-
lapsing multiple statements.
The first Delphi round was performed online:
the document containing the first version of the
statements was made available via a secure ser-
ver to the members of the scientific board, who
were asked to express their agreement or dis-
agreement on each statement using a 5-point
Likert scale (1, strongly disagree; 2, disagree; 3,
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undecided; 4, agree; 5, strongly agree). Positive
consensus was achieved when the proportion of
voters selecting items 4 and 5 was C 80%.
In December 2016, a plenary BRIDGE meet-
ing was organized to further discuss the state-
ments and the supporting literature and get
feedback from a wider audience of clinicians
composed of rheumatologists, dermatologists
and gastroenterologists selected to represent
IMID management over the entire national
territory. To improve discussion, the clinicians
were first subdivided into interdisciplinary
groups to discuss the statements with the sci-
entific board and the bibliographic fellows and
asked to express their agreement or disagree-
ment afterward in a voting session held during
the meeting, using an iPad application. The
results of the voting were not part of the Delphi
process and were collected only to investigate
the opinion of a wider audience of clinicians.
•Identification of questions
•Formation of scientific board
Ph
as
e 
1
April 2016 – Meeting
(steering committee)
July 2016 – Meeting
(scientific board)
December 2016  – March 2017
(scientific board)
(scientific board)
October 2016 – Meeting
(scientific board and 
bibliographic fellows)
December 2016 – BRIDGE meeting
(scientific board bibliographic
fellow, 45 clinicians)
(bibliographic fellows)
•Definition of strategies for
  systematic review of literature
•Further definition of questions
Ph
as
e 
3
Ph
as
e 
2
•Systematic review of literature
•Preliminary version of statements
  (9 questions/52 statements)
•Discussion and revision of
  preliminary version of statements
•Production of statements to be
submitted to Delphi voting
  (7 questions/13 statements)
•Delphi first round (online voting)
•Presentation and discussion of the 
  13 statements
•Survey of clinicians’ opinion
•Revision of statements
•Delphi second round (online voting)
•Finalizations statements
  (7 questions/13 statements)
Fig. 1 Process leading to the formulation of the 13 consensus statements about the multidisciplinary management of
spondyloarthritis-related immune-mediated inﬂammatory diseases (IMIDs)
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Phase 3
w?>In this phase, the results of the first online
Delphi voting were evaluated and made available
online via a secure server to all scientific board
members, along with the results of the survey
held during the plenary BRIDGE meeting. Each
member was asked to evaluate the results. Based
on comments emerging from the discussions
held at the BRIDGE meeting and on the results of
the first Delphi round, the statements were fur-
ther refined, with minor changes. The final ver-
sion of the statements was then submitted to a
second Delphi round, performed online as in the
first round and involving all members of the
scientific board, to confirm the achievement of
consensus on all statements.
RESULTS AND DISCUSSION
A positive consensus among the experts was
reached regarding almost all statements follow-
ing the first Delphi round. No consensus was
reached on two statements concerning the
composition of the multidisciplinary team (75%
of the experts agreed, 15% were uncertain, and
10% disagreed on the inclusion of ophthalmol-
ogists in the IMID team; 75% agreed, 20% were
uncertain, and 5% disagreed on the need to
provide psychologic support to IMID patients).
Based on a discussion among the panel members,
the wording of a few statements was changed for
the sake of clarity and to reduce redundancies.
No changes to the meaning of the statements
were made. After the second Delphi round, full
positive consensus was reached on all state-
ments. The only statement for which the positive
consensus was not full (100%) was that con-
cerning the composition of the IMID team, with
5% of the experts disagreeing on each one of the
items related to this issue and 5–10% being
uncertain about them. Questions and statements
are shown in Table 1, along with the agreement
level reached after the second Delphi round.
In the following sections, we present the evi-
dence that led to the formulation of each state-
ment and to the final consensus. We are aware
that relevant data may have been published after
the last update of the literature searches (October
2016) and that this may constitute an important
limitation of our study. This study may also be
limited in terms of evidence supporting the
effectiveness of the multidisciplinary approach
(i.e., few published articles and especially in the
dermatologic-rheumatologic field for PsA-Pso).
However, the current work, in addition to the
evidence in the literature, has also used an expert-
based approach and emphasizes the importance
of the multidisciplinary approach in stimulating a
broader application that may eventually lead to
more studies being published on the subject.
Rationale for a Multidisciplinary
Approach to SpA-Related IMID
Management (Statements 1a, 1b, 1c)
A large body of evidence from epidemiologic
studies indicates that patients with chronic
inflammatory conditions including Pso, PsA,
SpA and IBD are frequently affected by other
IMIDs. Up to 30% of patients with Pso are also
affected by PsA [20, 21]. According to the results
of a recent meta-analysis,* 10–15% of patients
with Pso have undiagnosed PsA [22]. A retro-
spective study analyzing 2006–2010 data from
the UK Clinical Practice Research Datalink
including patients with Pso (n = 27,672) and
PsA (n = 1952) has shown that patients with
severe Pso have significantly higher rates of
comorbidities, including arthritis, than those
with mild Pso; patients with PsA have signifi-
cantly higher rates of arthritis and ankylosing
spondylitis than those with severe Pso [23]. The
coexistence of several IMIDs is also widely
documented for SpA and in particular ankylos-
ing spondylitis. According to a meta-analysis of
143 studies reporting the prevalence of uveitis,
Pso and IBD in patients with ankylosing
spondylitis (n = 44,372), the pooled prevalences
of these conditions were 25.8%, 9.3% and 6.8%,
respectively [24]. As for the coexistence of var-
ious IMIDs in patients with IBD, a recent study
involving a European cohort of 1145 IBD
patients followed up for 10 years revealed a
greater likelihood that patients with CD would
develop extra-intestinal manifestations versus
those with UC (20.1% vs. 10.4%, p\0.001) [25].
Arthritis was the most frequently reported
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Table 1 Consensus statements on overarching principles concerning the multidisciplinary approach to the management of
spondyloarthritis-related immune-mediated inﬂammatory diseases (IMIDs)
Question Statement Consensus
degree (%)
1. IMIDs and multidisciplinary approach: what is the
context?
1a. Epidemiologic, clinical and prevalence studies
demonstrate that patients with IMIDs, such as those
with psoriasis, spondyloarthritis, inﬂammatory bowel
diseases and non-infectious uveitis, have a higher risk of
developing another related IMID than the normal
population
100%
1b. IMIDs including psoriasis, spondyloarthritis,
inﬂammatory bowel diseases and non-infectious uveitis
are interrelated, since they can occur concomitantly in
the same patient and may share a similar genetic
background. The use of drugs acting on pathways
common to more than one IMID may lead to improved
control and compliance in patients affected by more
than one IMID
100%
1c. A multidisciplinary approach in the management of
patients can result in a more extensive evaluation of
diseases and a more comprehensive treatment approach
compared with traditional consultation. The goals of a
multidisciplinary team include increasing the sensitivity
in diagnosing a concomitant IMID, improving the
decision-making process in IMID management and
increasing patient satisfaction and adherence
100%
2. Could an IMID team ensure a practical and
effective implementation of the multidisciplinary
approach?
2. A multidisciplinary team can play a key role in the
prompt diagnosis, referral, clinical management and
follow-up of patients with IMID
100%
3. How could an IMID team increase the level of care
throughout the pre-diagnosis, diagnosis and follow-
up phases?
3. A multidisciplinary team could improve patient
management as early referral and diagnosis, shared
therapeutic strategy, patient awareness and follow-up
programs are crucial for high-quality care. Furthermore
the introduction of specialist nurses improves the level of
care for both in- and outpatients
100%
4. Could the multidisciplinary approach be measured
as an additional value?
4. Early recognition of the associated IMID and timely
therapy may improve patient outcomes and prevent
long-term complications
100%
5. What are the goals of the IMID team? 5. The goals of the IMID team should be: to provide an
‘‘early diagnosis’’ of any additional IMID; to optimize
treatment, so as to improve patients’ quality of life and
ensure the efﬁcient use of available healthcare resources
100%
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Table 1 continued
Question Statement Consensus
degree (%)
6. Which tools can be used to achieve these goals? 6. Clinical examination, laboratory and instrumental tests
indicated for speciﬁc conditions and patient-reported
outcome tools are essential for IMID diagnosis and
follow-up. However, no standardized referral tools for
IMIDs are available at present. Deﬁning shared ‘‘red
ﬂags’’ would make early referral and diagnosis possible for
general practitioners and IMID team specialists
100%
7. Which specialists should be included in the IMID
team?
In addition to a dermatologist, gastroenterologist and
rheumatologist, the IMID team should include an
ophthalmologist, psychologist, general practitioner,
pediatrician and nurse:
7a. An ophthalmologist should always be involved in the
multidisciplinary management of IMIDs because eye
complications are frequent and serious and may impact
the patients’ quality of life with skin, musculoskeletal or
intestinal symptoms. IMID specialists should improve
their ophthalmologic knowledge and vice versa to
optimize specialist-ophthalmologist interaction and to
implement shared management during treatment and
follow-up
85%
7b. The psychologic status of IMID patients should be
taken into account during management of the disease.
An appropriate psychologic support would improve the
relationship with patients and increase compliance
during treatment and follow-up
90%
7c. General practitioners should be trained to recognize
IMIDs early to reduce delays in diagnosis. General
practitioners would therefore become an integral part of
the patient awareness and educational process
90%
7d. Cooperation with suitably trained IMID nurses could
improve patient management by monitoring access to
healthcare facilities and improving patient education
90%
7e. At present no standardized transition care models exist
that can only be applied to IMIDs. Models should be
based on an integration between professionals involved
in different healthcare settings (adult/pediatric care)
95%
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extra-intestinal manifestation (12.9% vs. 8.1%,
p = 0.01). The fact that CD patients are signifi-
cantly more affected than UC patients by extra-
intestinal manifestations was also reported by
others [26]. Finally, a recent meta-analysis
including 71 studies reporting the prevalence of
SpA in IBD patients found that the pooled
prevalence was 13% for arthritis, 10% for
sacroiliitis and 3% for spondylitis [27].
The coexistence of IMIDs in the same patient
and within families can be explained by the fact
that they have a common genetic background
and share pathogenetic mechanisms [1–4, 28].
The role of the human leukocyte antigen (HLA)
B27 in conferring susceptibility to ankylosing
spondylitis and other IMIDs is well established,
although the mechanistic details of how HLA-
B27 mediates joint inflammation have not been
fully elucidated [29, 30]. Perhaps the most
striking evidence of the overlapping patho-
physiology of IMIDs comes from the clinical
efficacy of biologic therapies targeting the same
inflammatory pathway in a variety of IMIDs.
This is reflected in the wide spectrum of IMID
indications for TNF-a inhibitors. For example,
adalimumab, a monoclonal antibody against
TNF-a, is effective in RA, PsA, Pso (plaque pso-
riasis), IBD (CD, UC, pediatric CD and intestinal
Behc¸et’s disease), ankylosing spondylitis, non-
radiographic axial SpA and juvenile idiopathic
arthritis [28].
Role of the Multidisciplinary Team
in the Implementation of Integrated SpA-
Related IMID Management (Statement 2)
Recent literature suggests multiple roles for the
multidisciplinary team including: improving
diagnosis, optimizing treatment on an in- and
outpatient basis, and enhancing patient satis-
faction and involvement in their own care [31].
A multidisciplinary approach to patients with
moderate-to-severe PsA was associated with
improved treatment of skin and joint symptoms
and a higher level of patient satisfaction,
despite long waiting times [32]. According to
the experience from a US combined dermatol-
ogy and rheumatology clinic in the manage-
ment of Pso and PsA, almost half of the more
than 500 patients referred to the clinic during a
6-year period received a revised diagnosis that
was different from the diagnosis received at
other centers [33]. Compared with before they
attended the combined clinic, patients were
more likely to be prescribed systemic medica-
tion and biologics. Similar results were reported
by a Spanish study describing the 4-year expe-
rience of a new multidisciplinary Pso and PsA
unit [34]. The multidisciplinary strategy
improved diagnosis and symptom control and
facilitated early diagnosis of SpA and timely
treatment initiation [34]. Preliminary data from
the experience of an Italian center with the
integrated management of 145 patients with
PsA by a dermatologist and a rheumatologist are
also promising [35]. A positive impact on dis-
ease activity and quality of life (QoL) was
reported after only 12 weeks of integrated
management.
Impact of the Multidisciplinary Team
on All Stages of SpA-Related IMID
Management from Presentation to Long-
Term Follow-Up (Statement 3)
Multidisciplinary care should be provided from
the earliest steps of patient management. In
patients with Pso, for example, the early detec-
tion of comorbidities is increasingly recognized
as a crucial step in patient management. The
4-year experience of the Spanish PSORD multi-
disciplinary model that operates according to
well-defined referral criteria has shown that this
approach enables early diagnosis of PsA and
subsequent timely treatment initiation [34]. A
positive impact of a multidisciplinary care pro-
gram on the timely initiation of intensive
therapy has also been reported in a study com-
paring an integrated care program with the
current standard of care in patients with early
RA [36]. Regarding the role of the multidisci-
plinary approach during treatment and follow-
up, a prospective study evaluating medical
outcomes in 20 patients with RA receiving
multidisciplinary management showed that all
patients reported significant improvements in
QoL after 3 and 6 months [37] and that this
effect was sustained.
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Outcome Measures
for the Multidisciplinary Approach
(Statement 4)
Developing and selecting adequate outcome
measures of the effectiveness of integrated IMID
care are challenging. In RA, the context in
which multidisciplinary team care has been
most extensively investigated, the use of func-
tion-specific and patient-related outcomes is
recommended [38]. In a 10-year study, 55
patients with early RA were treated with a
multidisciplinary approach including early and
active use of disease-modifying anti-rheumatic
drugs (DMARDs), outcome measures included
HR-QoL (NHP), disease activity (DAS28), func-
tion (HAQ) and joint destruction (Larsen scores)
[39]. Overall, all NHP dimensions except social
isolation improved significantly during the first
6 months and remained favorable up to
10 years. Early improvements in HR-QoL were
sustained over the 10-year observation period
for patients with recent-onset RA treated with a
multidisciplinary strategy that included early
intensive DMARD therapy. A randomized con-
trolled study in 46 patients with ankylosing
spondylitis was conducted to compare a 3-week
in-patient multidisciplinary rehabilitation pro-
gram with conventional care [40]. Primary
outcomes were disease activity measured with
the BASDAI and function measured with the
BASFI; secondary outcomes included well-be-
ing, spinal and hip mobility and HR-QoL mea-
sured with the SF-36. The 3-week
multidisciplinary rehabilitation program was
found to be more effective than conventional
treatment in most outcomes considered.
Goals of the Multidisciplinary Team
(Statement 5)
A large body of evidence from studies in
patients with psoriatic disease suggests that one
of the goals of the multidisciplinary approach is
the early diagnosis of the IMIDs that coexist
with the disease that has been diagnosed first.
As Pso precedes PsA in 75–80% of patients,
dermatologists clearly play a key role in the
early diagnosis of PsA, and the collaboration
among dermatologists, radiologists and
rheumatologists is crucial [41, 42]. Evidence
shows that prompt initiation of treatment for
PsA in patients with Pso can prevent the pro-
gression of joint damage and functional dis-
ability [43, 44]. Even a 6-month delay from
articular symptom onset to the first visit to the
rheumatologist contributes to the development
of peripheral joint erosions and worse func-
tional impairment [45]. The importance of
cooperation between dermatologists and
rheumatologists needs to be emphasized to
improve the early detection of PsA and enable
timely initiation of adequate treatment [46, 47].
Another important goal of the multidisci-
plinary team is to improve patient-physician
communication. In the IBD setting, there is a
generally recognized need to improve commu-
nication between patients and physicians espe-
cially regarding QoL and new treatment options
[48]. The patient-physician relationship has
been identified as one of the factors that affects
adherence to prescribed medication, which is a
common problem in UC [49, 50]. In particular,
the patient-physician relationship appears to be
critical in encouraging adherence through
patient education, open communication and
agreement on the value of the prescribed treat-
ment [50].
Tools for Achieving the Goals (Statement
6)
In the setting of psoriatic disease, considerable
effort has been devoted in recent years to the
development of screening tools for the early
diagnosis of PsA in patients with Pso, and vali-
dated PsA screening tools are available. Four
validated screening tools have been recently
compared in Pso patients [ToPAS II (Toronto
Psoriatic Arthritis Screen II), PASE (Psoriatic
Arthritis Screening and Evaluation), PEST (Pso-
riasis Epidemiology Screening Tool) and EARP
(Early Arthritis for Psoriatic Patients] [51]. EARP
was found to have the most sensitivity while
ToPAS the most specificity. The NICE guidelines
recommend the annual use of PEST on all Pso
patients without PsA [52, 53]; in the authors’
experience, PEST and EARP are the most useful
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and practical screening tools for PsA. Magnetic
resonance imaging (MRI) and ultrasonography
are other useful tools for the early diagnosis of
PsA [54].
In the field of CD, recent efforts have been
devoted to the identification of signs and
symptoms (red flags) that should warn clini-
cians about the presence of this condition
[55, 56]. A Red Flag index has been recently
developed to improve early diagnosis of CD, but
as yet it has not been validated [55].
Interesting new tools are available using
mobile internet technologies. For example, a
mobile internet-support service (t-RAppen) has
been recently developed to improve self-man-
agement of physical activity in RA patients [57].
In recent years, patient-reported outcomes
(PROs) have attracted interest as potential
assessment tools. A recent study has evaluated
alerts generated by a PRO measure-based algo-
rithm for monitoring RA patients and found
that the use of the algorithm to screen sched-
uled visits reduces the chance of missing
patients in need of medication intensification
[58]. A 7-year follow-up study has evaluated
PROs as assessment tools and predictors of long-
term prognosis in patients with RA [59]. How-
ever, the use of EULAR criteria including PRO
for remission is controversial. The study found
that the criteria are stringent but important to
achieve sustained remission in RA.
When conventional radiography fails to
provide conclusive information, MRI tech-
niques are useful for the differential diagnosis,
for example, in detecting early stage RA and PsA
in the small hand and foot joints [60]. For the
evaluation of hand and feet joints and sur-
rounding soft tissue structures in RA and PsA,
ultrasound and other imaging techniques are
also useful [61].
The first EULAR recommendations for the
use of imaging in the diagnosis and manage-
ment of SpA were published in 2015 [62]. The
recommendations encompass the entire spec-
trum of SpA and evaluate the full role of com-
monly used imaging techniques, namely:
conventional radiography, ultrasound, MRI,
computed tomography (CT), positron emission
tomography, single-photon emission CT, dual-
emission X-ray absorptiometry and
scintigraphy. The European Crohn’s and Colitis
Organisation (ECCO) recommends upper gas-
trointestinal endoscopy in the assessment of
pediatric and adolescent IBD for classification
purposes, and in general endoscopy is recom-
mended to confirm diagnosis and in cases
where management needs to be changed [63].
The ECCO guidelines on imaging techniques in
IBD state that radiologic imaging techniques
complement endoscopic assessment and can
assist in the detection and staging of CD [64]; in
addition, they state that imaging should be used
at first diagnosis for staging and to monitor
follow-up. Imaging techniques recommended
for IBD include ultrasound, CT, MRI and
scintigraphy with radiolabeled leukocytes [64].
Barium contrast and plain film radiology can
also be used; however, the use of plain-film
radiography is decreasing in favor of ultrasound
and CT [64].
Specialists to Be Included in the IMID
Team (Statements 7a, 7b, 7c, 7d, 7e)
Direct evidence supporting the inclusion of an
ophthalmologist in the multidisciplinary team
managing IMIDs is currently lacking. However,
the high prevalence of uveitis in IMID patients
justifies the presence of an ophthalmologist in
the multidisciplinary team to manage eye dis-
ease manifestations that can be very bother-
some [65, 66]. A study from the Spanish
AQUILEA cohort estimated a 2-year incidence
of new uveitis cases in patients with SpA of
3.1%, predominantly in patients with ankylos-
ing spondylitis [67]. Conversely, it has been
estimated that approximately 40% of patients
presenting with idiopathic acute anterior uveitis
have undiagnosed SpA [68]. An algorithm for
the assessment of patients with acute anterior
uveitis has been recently developed to assist
ophthalmologists in the referral of patients to
rheumatology clinics for early SpA diagnosis
[68].
The literature documenting psychologic dis-
tress in IMIDs is extensive [69–72]. Psychologic
distress in RA patients has a negative effect on
pain outcomes [71, 73] and has been associated
with poor adherence to treatment [74–76]. A
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few studies, mostly in RA and Pso, have evalu-
ated the impact of psychologic assistance on
outcomes, with mixed results [77, 78].
International guidelines recommend the
involvement of general practitioners (GPs) in
the RA multidisciplinary team [9]. Various
studies have investigated the relationship
between GPs and rheumatologists regarding the
referral of patients with inflammatory rheu-
matic diseases from primary care to rheuma-
tology clinics [79–82]. According to the results
of a survey among Flemish GPs, decisions about
intensive treatment initiation in early RA
should be made by rheumatologists [79].
Reported barriers to intensive treatment initia-
tion included patients’ resistance and non-ad-
herence, lack of GP involvement and
unsatisfactory collaboration with rheumatology
services. A study assessing the knowledge of SpA
among GPs showed that GPs are aware of classic
features of ankylosing spondylitis [81, 82].
However, knowledge about the disease spec-
trum is limited, and early detection is rare.
Addressing these issues in training programs
may improve recognition of SpA in primary
care.
The role of nurses in multidisciplinary team
care of IMIDs has been investigated extensively,
with most studies being in the field of chronic
rheumatic diseases [83–92]. A Delphi consensus
statement on multidisciplinary teams in IBD
recommended the inclusion of an IBD nurse in
such a team [31], and in general the inclusion of
nurses in the IMID multidisciplinary team is
widely recommended [9, 93]. However, the
position of nurses within the multidisciplinary
team varies markedly depending on the coun-
try. In addition, healthcare providers corre-
sponding to the ‘‘nurse practitioner’’ of the UK
or US healthcare systems do not exist in many
countries, including Italy. As a consequence,
many of the data and recommendations present
in the literature about the role of nurses in
multidisciplinary care of IMID may not be
generally applicable. Recommendations defin-
ing the role of nurses in addressing unmet needs
in the management of RA have been published
[94]. The evidence shows that nurses usually
spend more time with patients than doctors do;
they also engage more in the socio-emotional
process of establishing a relationship with the
patient [92]. Therefore, nurses are in a unique
position to explore patient needs and address
unmet needs, educate about treatment and self-
injection techniques, monitor safety and pro-
gress, and coordinate treatment within the
multidisciplinary setting [94]. The role of nurses
in the education of psoriatic patients about
healthier lifestyle habits that can reduce the risk
of metabolic complications associated with Pso
has also been suggested [95].
CONCLUSIONS
It is interesting to note that the 2009 NICE
guidelines for the treatment of RA, while rec-
ognizing the lack of supporting evidence, rec-
ommend multidisciplinary team care because of
the services it can provide to patients with RA
[9]. The NICE guidelines also underline
patients’ perception of non-clinician members
of the team (e.g., specialist nurses) as having
more time for them [9]. Also lacking are guide-
lines recommending IMID-specific models of
multidisciplinary management.
A recent survey among Spanish dermatolo-
gists and rheumatologists, who provided mul-
tidisciplinary care for patients with PsA,
investigated different models [96]. Two essential
characteristics for the implementation of inter-
disciplinary model were identified: involvement
and empathy of team members and well-de-
fined referral criteria. In the present Delphi
process, all of the experts involved agreed about
the related nature of IMIDs and the existence of
a high prevalence of multiple IMIDs in a single
patient. One hundred percent agreement was
also obtained regarding the fact that a multi-
disciplinary approach can result in a more
extensive evaluation of diseases and a more
comprehensive approach to treatment. It was
unanimously agreed that the goals of a multi-
disciplinary team for SpA-related IMIDs should
be to increase the diagnosis of concomitant
IMIDs to improve the decision-making process
during management and to increase patient
satisfaction and adherence to treatment. Early
referral and diagnosis, early recognition of
concomitant IMIDs and optimizing treatment
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to improve patient QoL are some of the
advantages of using multidisciplinary teams for
SpA-related IMIDs. To be effective, the expert
panel agreed that a multidisciplinary team
should be equipped with the appropriate tools
for diagnosis and follow-up and at a minimum
the multidisciplinary team should include a
dermatologist, gastroenterologist and rheuma-
tologist; high agreement (90–95%) was also
obtained regarding the importance of providing
psychologic support via a psychologist and
involving an ophthalmologist, GPs and nurses
in multidisciplinary care.
We are aware that evidence supporting the
effectiveness of the strategy used here is limited
as only a few published studies have specifically
assessed the impact of the multidisciplinary
approach in terms of diagnostic and therapeutic
improvement. Nonetheless, the current study
has incorporated data from the literature (i.e.,
systematic research, therefore evidence based)
with the opinion of experts (i.e., specialists of
various disciplines with appropriate scientific
background and direct clinical experience in
multidisciplinary management). Importantly,
this is the first study that has analyzed the
advantages of the multidisciplinary approach
from a double point of view (evidence-based
plus personal experience) and that aims to
spread the application for a better management
of complex pathologies such as SpA-related
IMIDs. Future multicenter studies with exten-
sive case studies that specifically evaluate the
impact of the multidisciplinary approach are
needed. It would also be of interest to evaluate
the advantages of the multidisciplinary
approach in terms of economic benefits (i.e.,
early diagnosis and therefore lower disability,
appropriate use of diagnostic methods, appro-
priate and shared use by more specialists of
high-cost drugs).
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